• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Pfizer (Group)

At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. *

 

	Industry	pharmaceutical
	Street	235 East 42nd Street
	City	10017 New York, NY
	Tel	+1-212-733-2323
		Address record changed: 2008-12-07
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	48,613,000,000 (revenue, consolidated (2007) 2007-12-31)
	Profit	8,298,000,000 (2007-12-31)
		* Document for �About Section�: Beckman Coulter, Inc.. (12/1/10). "Press Release: Next-generation Cell Sorter from Beckman Coulter Enables Multi-color Flow Cytometry Studies. MoFlo Astrios Features Bead-less Drop Delay Determination". Orange County, CA.
		Record changed: 2018-12-15

Advertisement

More documents for Pfizer (Group)

• [1] Pfizer Inc.. (5/8/19). "Press Release: Pfizer Acquires Clinical-Stage Biotech Therachon". New York, NY & Basel....
• [2] Pfizer Inc.. (5/7/19). "Press Release: European Commission Approves Lorviqua (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer"....
• [3] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy". Brisbane, CA & New York, NY....
• [4] Vivet Therapeutics S.A.S.. (3/20/19). "Press Release: Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics". Paris & New York, NY....
• [5] Merck KGaA. (2/16/19). "Press Release: Pivotal Phase III Data for Bavencio (avelumab) plus Inlyta (axitinib) in Advanced Renal Cell Carcinoma Published in The New England Journal of Medicine [Not intended for US, Canada and UK-based media]". Darmstadt &...
• [6] Merck KGaA. (2/11/19). "Press Release: FDA Accepts sBLA and Grants Priority Review for Bavencio (avelumab) plus Inlyta (axitinib) for the Treatment of Advanced Renal Cell Carcinoma [Not intended for US, Canada and UK-based media]". Darmstadt....
• [7] Merck KGaA. (11/19/18). "Press Release: Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer [Not intended for US, Canada and UK-based media]". Darmstadt....
• [8] Spark Therapeutics, Inc.. (11/6/18). "Press Release: Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress". Philadeliphia, PA....
• [9] BioNTech AG. (8/16/18). "Press Release: BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza". Mainz & New York, NY....
• [10] Sygnature Discovery Ltd.. (6/1/18). "Press Release: Sygnature Discovery Focuses on US Expansion with the Appointment of Dr Bill Marathias". Nottingham....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.